Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

Summary

Antibody formation to factor VIII (FVIII) remains the greatest clinical and diagnostic challenge to the haemophilia-treating physician. Current guidance for testing for inhibitory FVIII antibodies (inhibitors) recommends the functional Nijmegen-Bethesda assay (NBA). A FVIII ELISA offers a complementary, immunological approach for FVIII antibody testing. It was the aim of this study to retrospectively evaluate the performance of a FVIII ELISA (index) for detection of FVIII antibodies, compared with the NBA (reference). All samples sent for routine FVIII antibody testing at two haemophilia Comprehensive Care Centres, were tested in parallel using the NBA and a solid-phase, indirect FVIII ELISA kit (Immucor). A total of 497 samples from 239 patients (severe haemophilia A=140, non-severe haemophilia A=85, acquired haemophilia A=14) were available for analysis. Sixty-THree samples tested positive by the NBA (prevalence 12.7 %, 95 % confidence interval [CI], 9.9–15.9 %), with a median inhibitor titre of 1.2 BU/ml (range 0.7–978.0). The FVIII ELISA demonstrated a specificity of 94.0 % (95 %CI, 91.3–96.0), sensitivity of 77.8 % (95 %CI, 65.5–87.3), negative predictive value of 96.7 % (95 %CI, 94.5–98.2), positive predictive value 65.3 % (95 %CI, 53.5–76.0), negative likelihood ratio 0.2 (95 %CI, 0.1–0.4), positive likelihood ratio 13.0 (95 %CI, 8.7–19.3) and a diagnostic odds ratio of 54.9 (95 %CI, 27.0–112.0). Strong positive correlation (r=0.77, p< 0.001) was seen between the results of the NBA (log adjusted) and FVIII ELISA optical density. In conclusion, FVIII ELISA offers a simple, specific, surveillance method enabling batch testing of non-urgent samples for the presence of FVIII antibodies.

Keywords

Factor VIII inhibitors - haemophilia A - ELISA - Bethesda - sensitivity

• References

• 1 Gouw SC, van den Berg HM, Fischer K. et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046-4055.
• 2 Collins PW, Chalmers E, Hart DP. et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-170.
• 3 Hay CR, Palmer B, Chalmers E. et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-6370.
• 4 Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE. et al. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia 2012; 18: 263-267.
• 5 Eckhardt CL, van Velzen AS, Peters M. et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954-1962.
• 6 Collins W, Chalmers E, Hart D. et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162: 758-773.
• 7 Huth-Kuhne A, Baudo F, Collins P. et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-575.
• 8 Kasper CK, Aledort L, Aronson D. et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
• 9 Verbruggen B, Novakova I, Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
• 10 Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35: 786-793.
• 11 Kitchen S, Jennings I, Preston FE. et al. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009; 35: 778-785.
• 12 Peerschke EI, Castellone DD, Ledford-Kraemer M. et al. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2009; 131: 552-558.
• 13 Favaloro EJ, Bonar R, Duncan E. et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39: 504-511.
• 14 Favaloro EJ, Bonar R, Duncan E. et al. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Hae-most 2006; 96: 73-78.
• 15 Martin PG, Sukhu K, Chambers E. et al. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999; 21: 125-128.
• 16 Shetty S, Ghosh K, Mohanty D. An ELISA assay for the detection of factor VIII antibodies – comparison with the conventional Bethesda assay in a large cohort of haemophilia samples. Acta Haematol 2003; 109: 18-22.
• 17 Ling M, Duncan EM, Rodgers SE. et al. Low detection rate of antibodies to nonfunctional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1: 2548-2553.
• 18 Towfighi F, Gharagozlou S, Sharifian RA. et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84-90.
• 19 Sahud MA, Pratt KP, Zhukov O. et al. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 2007; 13: 317-322.
• 20 Klintman J, Hillarp A, Berntorp E. et al. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol 2013; 163: 385-392.
• 21 Krudysz-Amblo J, Parhami-Seren B, Butenas S. et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113: 2587-2594.
• 22 Zakarija A, Harris S, Rademaker AW. et al. Alloantibodies to factor VIII in haemophilia. Haemophilia 2011; 17: 636-640.
• 23 Lebreton A, Lapalud P, Chambost H. et al. Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thromb Haemost 2011; 105: 954-961.
• 24 Mondorf W, Klinge J, Luban NL. et al. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. Haemophilia 2001; 7: 13-19.
• 25 Scandella D, Mondorf W, Klinge J. The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Haemophilia 1998; 4: 546-551.
• 26 White GC, Rosendaal F, Aledort LM. et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
• 27 Verbruggen B, van HW, Novakova I, Lillicrap D. et al. A 4 % solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002; 88: 362-364.
• 28 Miller CH, Rice AS, Boylan B. et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost 2013; 11: 1300-1309.
• 29 European Medicines Agency.. Report of Expert Meeting on Factor VIII Products and Inhibitor Development. 2007. London: European Medicines Agency.;
• 30 Moore GW, Maloney JC, Ngundu CJ. et al. Assessing lowest limits of detection of FVIII inhibitor assays. EAHAD. 2010
• 31 Viel KR, Ameri A, Abshire TC. et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-1627.
• 32 Sahud M, Zhukov O, Mo K. et al. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies. Haemophilia 2012; 18: 777-781.
• 33 Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
• 34 Genders TS, Spronk S, Stijnen T. et al. Methods for calculating sensitivity and specificity of clustered data: a tutorial. Radiology 2012; 265: 910-916.
• 35 Glas AS, Lijmer JG, Prins MH. et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-1135.
• 36 Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. Br Med J 2004; 329: 168-169.
• 37 Turkey JW. Comparing Individual Means in the Analysis of Variance. Biometrics 1949; 5: 99-114.
• 38 Bossuyt PM, Reitsma JB, Bruns DE. et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Br Med J 2003; 326: 41-44.
• 39 Kitchen S, McCraw A, Echenagucia M. Diagnosis of Hemophilia and Other Bleeding Disorders : A Laboratory Manual. Second Edition ed.. Montréal: World Federation of Hemophilia (WFH);; 2010
• 40 Batty P, Platton S, Bowles L. et al. Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A. Br J Haematol 2014; 166: 953-956.
• 41 Sahud M, Ruden S, Soriano C. et al. Characterization of Factor VIII Autoanti-bodies with Complex Reaction Kinetics is Improved by Heat Inactivation of the Test Plasma to Remove Residual Factor Activity. J Thromb Haemost 2005; 3: P0651.
• 42 Bossuyt PM, Irwig L, Craig J. et al. Comparative accuracy: assessing new tests against existing diagnostic pathways. Br Med J 2006; 332: 1089-1092.
• 43 Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press; 2003
• 44 Verbruggen B, van Heerde W, Novakova I. et al. A 4 % solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002; 88: 362-364.
• 45 Kershaw GW, Chen LS, Jayakodi D. et al. Validation of 4 % albumin as a diluent in the Bethesda Assay for FVIII inhibitors. Thromb Res 2013; 132: 735-741.
• 46 Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-1119.
• 47 Astermark J, Voorberg J, Lenk H, DiMichele D, Shapiro A, Tjonnfjord G. et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-572.
• 48 Vincent AM, Lillicrap D, Boulanger A. et al. Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates. Haemophilia 2009; 15: 374-6.
• 49 Klintman J, Hillarp A, Donfield S. et al. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. Haemophilia 2013; 19: 106-112.
• 50 Butenas S, Krudysz-Amblo J, Rivard GE, Mann G. Product-dependent anti-factor VIII antibodies. Haemophilia 2013; 19: 619-625.